SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Approves AstraZeneca’s IMFINZI Regimen for Bladder Cancer

The FDA approved perioperative IMFINZI with neoadjuvant enfortumab vedotin-ejfv, followed by adjuvant IM.

AZN

Related stories